Trazimera (trastuzumab-qyyp)

aBL 761081

Trazimera (trastuzumab-qyyp)

aBL 761081

U.S. License Holder:

Pfizer Inc.

Date of License:

March-11-2019

Last Update:

December-08-2019

approved_indications FDA-Approved Indications


TRAZIMERA (trastuzumab-qyyp) is a HER2/neu receptor antagonist indicated for:

The treatment of HER2-overexpressing breast cancer;

The treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.

approved_indications Approved Foreign Follow-On Biologics / Biosimilars


Biosimilars Approved In The E.U.

Trazimera (Pfizer) (July-2018)

approved_indications Inter Partes Review Proceedings

PTAB Portal

IPR Case No(s):

U.S. Patent No.
7,807,799 (Reducing Protein A Leaching During Protein A Affinity Chromatography)

Patent Owner
Genentech, Inc.

Petitioner(s)
Hospira, Inc.

§ 102 Challenge
Y

Claim Types Challenged Under § 102
Manufacturing

§ 102 Challenge Instituted
Y

§ 103 challenge
Y

Claim Types Challenged Under § 103
Manufacturing

§ 103 Challenge Instituted
Y

Final Written Decision Issued
Y

Federal Circuit Appeal(s)
18-1933

IPR Status
Final Written Decision (All Instituted Claims Found Unpatentable); Federal Circuit Appeal Pending

U.S. Patent No.
7,846,441 (Treatment with anti-ErbB2 antibodies)

Patent Owner
Genentech, Inc.

Petitioner(s)
Hospira, Inc.; Pfizer Inc.

§ 102 Challenge
N

§ 103 challenge
Y

Claim Types Challenged Under § 103
Method of Treatment

§ 103 Challenge Instituted
Y (On Request for Rehearing)

Final Written Decision Issued
Y

Federal Circuit Appeal(s)
19-1263

IPR Status
Final Written Decision (All Instituted Claims Found Unpatentable); Federal Circuit Appeal Terminated as to Hospira and Pfizer, Pending with US as Intervenor

U.S. Patent No.
7,892,549 (Treatment with anti-ErbB2 antibodies)

Patent Owner
Genentech, Inc.

Petitioner(s)
Hospira, Inc.; Pfizer Inc.

§ 102 Challenge
N

§ 103 challenge
Y

Claim Types Challenged Under § 103
Method of Treatment

§ 103 Challenge Instituted
Y

Final Written Decision Issued
Y

Federal Circuit Appeal(s)
19-1265

IPR Status
Final Written Decision (All Instituted Claims Found Unpatentable); Federal Circuit Appeal Dismissed for Hospira, Motion for Samsung Bioepis to Withdraw as a Party Granted, Awaiting USPTO Director's Decision on Whether to Intervene

U.S. Patent No.
7,892,549 (Treatment with Anti-ErbB2 Antibodies)

Patent Owner
Genentech, Inc.

Petitioner(s)
Hospira, Inc.; Pfizer Inc.

§ 102 Challenge
Y

Claim Types Challenged Under § 102
Method of Treatment

§ 102 Challenge Instituted
N

§ 103 challenge
N

IPR Status
IPR Not Instituted

U.S. Patent No.
6,627,196 (Dosages for Treatment with Anti-ErbB2 Antibodies)

Patent Owner
Genentech, Inc.

Petitioner(s)
Hospira, Inc.; Pfizer Inc.

§ 102 Challenge
N

§ 103 challenge
Y

Claim Types Challenged Under § 103
Method of Treatment

§ 103 Challenge Instituted
Y

Final Written Decision Issued
Y

Federal Circuit Appeal(s)
19-1174

IPR Status
Final Written Decision (No Instituted Claim Found Unpatentable); Federal Circuit Appeal Dismissed

U.S. Patent No.
7,371,379 (Dosages for Treatment with Anti-ErbB2 Antibodies)

Patent Owner
Genentech, Inc.

Petitioner(s)
Hospira, Inc.; Pfizer Inc.

§ 102 Challenge
N

§ 103 challenge
Y

Claim Types Challenged Under § 103
Method of Treatment

§ 103 Challenge Instituted
Y

Federal Circuit Appeal(s)
19-1173

IPR Status
Final Written Decision (No Instituted Claim Found Unpatentable); Federal Circuit Appeal Dismissed

U.S. Patent No.
6,407,213 (Method for Making Humanized Antibodies)

Patent Owner
Genentech, Inc.

Petitioner(s)
Pfizer, Inc.

§ 102 Challenge
Y

Claim Types Challenged Under § 102
Composition of Matter

§ 102 Challenge Instituted
Y

§ 103 challenge
Y

Claim Types Challenged Under § 103
Composition of Matter

§ 103 Challenge Instituted
Y

Final Written Decision Issued
Y

IPR Status
Final Written Decision (Some Instituted Claims Unpatentable)

U.S. Patent No.
6,407,213 (Method for Making Humanized Antibodies)

Patent Owner
Genentech, Inc.

Petitioner(s)
Pfizer, Inc.

§ 102 Challenge
N

§ 103 challenge
Y

Claim Types Challenged Under § 103
Composition of Matter

§ 103 Challenge Instituted
Y

IPR Status
IPR Trial Ongoing

U.S. Patent No.
8,591,897 (Anti-ErbB2 Antibody Adjuvant Therapy)

Patent Owner
Genentech, Inc.

Petitioner(s)
Pfizer, Inc.

§ 102 Challenge
Y

Claim Types Challenged Under § 102
Method of Treatment

§ 102 Challenge Instituted
N

§ 103 challenge
Y

Claim Types Challenged Under § 103
Method of Treatment

§ 103 Challenge Instituted
N

IPR Status
IPR Not Instituted

U.S. Patent No.
8,591,897 (Anti-ErbB2 Antibody Adjuvant Therapy)

Patent Owner
Genentech, Inc.

Petitioner(s)
Pfizer, Inc.

§ 102 Challenge
N

§ 103 challenge
Y

Claim Types Challenged Under § 103
Method of Treatment

§ 103 Challenge Instituted
N

IPR Status
IPR Not Instituted

U.S. Patent No.
6,339,142 (Protein Purification)

Patent Owner
Genentech, Inc.

Petitioner(s)
Pfizer, Inc.

§ 102 Challenge
Y

Claim Types Challenged Under § 102
Composition of Matter Formulation

§ 102 Challenge Instituted
Y

§ 103 challenge
Y

Claim Types Challenged Under § 103
Composition of Matter Formulation

§ 103 Challenge Instituted
Y

Settled / Challenged Claims Disclaimed / Challenge Terminated
Terminated due to Settlement

IPR Status
Terminated after Institution due to Settlement

U.S. Patent No.
9,249,218 (Protein Purification)

Patent Owner
Genentech, Inc.

Petitioner(s)
Pfizer, Inc.

§ 102 Challenge
Y

Claim Types Challenged Under § 102
Formulation

§ 102 Challenge Instituted
Y

§ 103 challenge
Y

Claim Types Challenged Under § 103
Formulation

§ 103 Challenge Instituted
Y

Settled / Challenged Claims Disclaimed / Challenge Terminated
Terminated due to Settlement

IPR Status
Terminated after Institution due to Settlement

U.S. Patent No.
7,846,441 (Treatment with Anti-ERBB2 Antibodies)

Patent Owner
Genentech, Inc.

Petitioner(s)
Pfizer, Inc.

§ 102 Challenge
N

§ 103 challenge
Y

Claim Types Challenged Under § 103
Method of Treatment

§ 103 Challenge Instituted
Y; Joined with IPR2017-01121

Final Written Decision Issued
Y

IPR Status
Joined with IPR2017-01121; Final Written Decision (All Instituted Claims Found Unpatentable)

U.S. Patent No.
7,846,441 (Treatment with Anti-ERBB2 Antibodies)

Patent Owner
Genentech, Inc.

Petitioner(s)
Pfizer, Inc.

§ 102 Challenge
N

§ 103 challenge
Y

Claim Types Challenged Under § 103
Method of Treatment

§ 103 Challenge Instituted
N

IPR Status
IPR Not Instituted

U.S. Patent No.
6,339,142 (Protein Purification)

Patent Owner
Genentech, Inc.

Petitioner(s)
Pfizer, Inc.

§ 102 Challenge
Y

Claim Types Challenged Under § 102
Composition of Matter Formulation

§ 102 Challenge Instituted
N

§ 103 challenge
Y

Claim Types Challenged Under § 103
Composition of Matter Formulation

§ 103 Challenge Instituted
N

IPR Status
IPR Not Instituted; Motion for Joinder with IPR2017-02019 Denied

U.S. Patent No.
9,249,218 (Protein Purification)

Patent Owner
Genentech, Inc.

Petitioner(s)
Pfizer, Inc.

§ 102 Challenge
Y

Claim Types Challenged Under § 102
Formulation

§ 102 Challenge Instituted
N

§ 103 challenge
Y

Claim Types Challenged Under § 103
Formulation

§ 103 Challenge Instituted
N

IPR Status
IPR Not Instituted; Motion for Joinder with IPR2017-02020 Denied

approved_indications U.S. Patent Litigations

PACER

Case No(s):

U.S. Patent Nos.
6,121,428 (Protein Recovery) 6,242,177 (Methods and Compositions for Secretion of Heterologous Polypeptides) 6,331,415 (Methods of Producing Immunoglobulins, Vectors and Transformed Host Cells for Use Therein) 6,339,142 (Protein Purification) 6,407,213 (Method for Making Humanized Antibodies) 6,417,335 (Protein Purification) 6,489,447 (Protein Purification) 6,586,206 (Methods for Making Recombinant Proteins Using Apoptosis Inhibitors) 6,610,516 (Cell Culture Process) 6,620,918 (Separation of Polypeptide Monomers) 6,627,196 (Dosages for Treatment with Anti-ErbB2 Antibodies) 6,716,602 (Metabolic Rate Shifts in Fermentations Expressing Recombinant Proteins) 7,371,379 (Dosages for Treatment with Anti-ErbB2 Antibodies) 7,390,660 (Methods for Growing Mammalian Cells In Vitro) 7,449,184 (Fixed Dosing of HER Antibodies) 7,485,704 (Reducing Protein A Leaching During Protein A Affinity Chromatography) 7,501,122 (Treatment with Anti-ErbB2 Antibody Combinations) 7,807,799 (Reducing Protein A Leaching During Protein A Affinity Chromatography) 7,846,441 (Treatment with Anti-ERBB2 Antibodies) 7,892,549 (Treatment with anti-ErbB2 antibodies) 7,923,221 (Methods of Making Antibody Heavy and Light Chains having Specificity for a Desired Antigen) 7,993,834 (Detection of ErbB2 Gene Amplification to Increase the Likelihood of the Effectiveness of ErbB2 Antibody Breast Cancer Therapy) 8,044,017 (Protein Purification) 8,076,066 (Gene Detection Assay for Improving the Likelihood of an Effective Response to a HER2 Antibody Cancer Therapy) 8,314,225 (Heavy Chain Mutant Leading to Improved Immunoglobulin Production) 8,425,908 (Treatment with Anti-ErbB2 Antibodies) 8,440,402 (Gene Detection Assay for Improving the Likelihood of an Effective Response to a HER2 Antibody Cancer Therapy) 8,460,895 (Method for Producing Recombinant Proteins with a Constant Content of pCO2 in the Medium) 8,512,983 (Production of Proteins in Glutamine-Free Cell Culture Media) 8,574,869 (Prevention of Disulfide Bond Reduction During Recombinant Production of Polypeptides) 8,633,302 (Variable Tangential Flow Filtration) 8,691,232 (Extending Time to Disease Progression or Survival in Cancer Patients) 8,710,196 (Protein Purification) 8,771,988 (Protein Expression from Multiple Nucleic Acids) 8,822,655 (Pre-filtration Adjustment of Buffer Solutes) 9,249,218 (Protein Purification) 9,428,766 (Protein Expression from Multiple Nucleic Acids) 9,487,809 (Decreasing Lactate Level and Increasing Polypeptide Production by Downregulating the Expression of Lactate Dehydrogenase and Pyruvate Dehydrogenase Kinase) 9,493,744 (Methods for Viral Inactivation and Other Adventitious Agents) 9,714,293 (Production of Proteins in Glutamine-free Cell Culture Media) 9,868,760 (Protein Purification)

Plaintiffs
Genentech, Inc.; City of Hope

Defendants
Pfizer, Inc.

Status
Dismissed due to Settlement

BPCIA
Y

related articles Related News Articles


Venable Fitzpatrick’s BiologicsHQ Monthly Injection – October 2019 April Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D.; Ha Kung Wong November 11, 2019
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – March 2019 April M. Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D. April 5, 2019
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – July 2018 April M. Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D. August 3, 2018

Methodology

Information contained in the Venable Fitzpatrick BiologicsHQ database relates to FDA-approved drug products listed in the CDER Purple Book or on the FDA website (www.fda.gov). Information relating to FDA licensed products, FDA-approved indications, and aBLA and 505(b)(2) applications is obtained from public sources including the U.S. FDA website (www.fda.gov). Information relating to litigations is given only for cases active from January 31, 2010 onward. Information relating to foreign biosimilar / biologics follow-on products approved in Australia, Canada, the E.U., Japan and South Korea is from public sources. Statistics graphics are compiled from information contained in the Venable Fitzpatrick BiologicsHQ database.

Disclaimer

The individuals who maintain this site work for Venable LLP. The information, comments and links posted on this site do not constitute legal advice. No attorney-client relationship has been or will be formed by any communication(s) to, from or with the site and/or the author. For legal advice, contact an attorney at Venable LLP or an attorney actively practicing in your jurisdiction. Do not send any confidential or privileged information to the author; neither Venable LLP nor the author will assume any liability or responsibility for it. If you send any information, documents or materials to the site, you give permission for the author to include them on or in the site. No information, documents or materials you send to the site will be considered confidential or privileged by Venable LLP or its lawyers. Also, no such information, documents or materials will be returned to you. All decisions relating to the content belong to the author.

Subscribe for Future Updates

captcha